Repligen initiated with an Overweight at Wells Fargo

Wells Fargo analyst Timothy Daley initiated coverage of Repligen with an Overweight rating and $185 price target. The analyst recommends the shares based on the company’s “solid” acquisitions, R&D strategy, and competitive positioning in emerging therapies and biosimilars. It believes these will support “continued outsized earnings growth” and says fears of near-term headwinds are overblown.